Harrow, Inc. Increase (Decrease) in Deferred Charges
Harrow, Inc. (HROW) reported Increase (Decrease) in Deferred Charges of $410.94 thousand for the 173-month period ending 2012-12-31, per its 10-K filed 2013-03-18.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredCharges · last filed 2013-03-18
- Harrow, Inc. increase (decrease) in deferred charges for the quarter ending 2012-12-31 was $342.16K.
- Harrow, Inc. increase (decrease) in deferred charges for the quarter ending 2012-09-30 was $38.78K.
- Harrow, Inc. increase (decrease) in deferred charges for fiscal 2012 was $410.94K.
- Harrow, Inc. increase (decrease) in deferred charges for fiscal 2011 was $0.00.
| Period end | Increase (Decrease) in Deferred Charges 3 month | Increase (Decrease) in Deferred Charges 6 month | Increase (Decrease) in Deferred Charges 9 month | Increase (Decrease) in Deferred Charges 12 month | Increase (Decrease) in Deferred Charges 167 month | Increase (Decrease) in Deferred Charges 170 month | Increase (Decrease) in Deferred Charges 173 month |
|---|---|---|---|---|---|---|---|
| 2012-12-31 | $342.16K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $380.94K derived: sum of 2 quarters · filed 2013-03-18 | $410.94K 10-K · filed 2013-03-18 | $410.94K 10-K · filed 2013-03-18 | |||
| 2012-09-30 | $38.78K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-14 | $68.78K 10-Q · filed 2012-11-14 | $68.78K 10-Q · filed 2012-11-14 | ||||
| 2012-06-30 | $30.00K 10-Q · filed 2012-08-14 | $30.00K 10-Q · filed 2012-08-14 | |||||
| 2011-12-31 | $0.00 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |